Literature DB >> 10568907

Classification and definition of major flares in SLE clinical trials.

M Petri1, J Buyon, M Kim.   

Abstract

Multiple reliable and valid disease activities indices exist and have been used successfully in longitudinal studies. However, the definition of flare, using these intruments, has not been universally decided or accepted. Because flare is one of the three major patterns of lupus activity, it will remain an important outcome measure in both longitudinal and clinical trial studies.

Entities:  

Mesh:

Year:  1999        PMID: 10568907     DOI: 10.1191/096120399680411281

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  67 in total

1.  Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays.

Authors:  Quan-Zhen Li; Quan Li Zhen; Chun Xie; Tianfu Wu; Meggan Mackay; Cynthia Aranow; Chaim Putterman; Chandra Mohan
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

2.  Belimumab (benlysta): a breakthrough therapy for systemic lupus erythematosus.

Authors:  Raymond Lamore; Sapna Parmar; Khilna Patel; Olga Hilas
Journal:  P T       Date:  2012-04

3.  Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations.

Authors:  Hironari Hanaoka; Harunobu Iida; Tomofumi Kiyokawa; Yukiko Takakuwa; Kimito Kawahata
Journal:  Clin Rheumatol       Date:  2019-06-07       Impact factor: 2.980

4.  The effect of Ramadan fasting on quiescent systemic lupus erythematosus (SLE) patients' disease activity, health quality of life and lipid profile: a pilot study.

Authors:  Hamid Goharifar; Seyedeh Tahereh Faezi; Pedram Paragomi; Ali Montazeri; Arash Tehrani Banihashemi; Maryam Akhlaghkhah; Bahar Sadeghi Abdollahi; Zahra Kamazani; Mahmood Akbarian
Journal:  Rheumatol Int       Date:  2015-05-14       Impact factor: 2.631

5.  Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures.

Authors:  Laurent Chiche; Noémie Jourde-Chiche; Elizabeth Whalen; Scott Presnell; Vivian Gersuk; Kristen Dang; Esperanza Anguiano; Charlie Quinn; Stéphane Burtey; Yvon Berland; Gilles Kaplanski; Jean-Robert Harle; Virginia Pascual; Damien Chaussabel
Journal:  Arthritis Rheumatol       Date:  2014-06       Impact factor: 10.995

6.  Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity.

Authors:  José C Crispín; Brendan T Keenan; Michele D Finnell; Bonnie L Bermas; Peter Schur; Elena Massarotti; Elizabeth W Karlson; Lisa M Fitzgerald; Sukran Ergin; Vasileios C Kyttaris; George C Tsokos; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2010-05

7.  Belimumab in systemic lupus erythematosus: an update for clinicians.

Authors:  Susan S Kim; Kyriakos A Kirou; Doruk Erkan
Journal:  Ther Adv Chronic Dis       Date:  2012-01       Impact factor: 5.091

8.  A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

Authors:  Daniel J Wallace; William Stohl; Richard A Furie; Jeffrey R Lisse; James D McKay; Joan T Merrill; Michelle A Petri; Ellen M Ginzler; W Winn Chatham; W Joseph McCune; Vivian Fernandez; Marc R Chevrier; Z John Zhong; William W Freimuth
Journal:  Arthritis Rheum       Date:  2009-09-15

9.  Novel evidence-based systemic lupus erythematosus responder index.

Authors:  Richard A Furie; Michelle A Petri; Daniel J Wallace; Ellen M Ginzler; Joan T Merrill; William Stohl; W Winn Chatham; Vibeke Strand; Arthur Weinstein; Marc R Chevrier; Z John Zhong; William W Freimuth
Journal:  Arthritis Rheum       Date:  2009-09-15

10.  Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study.

Authors:  David Isenberg; Gerald B Appel; Gabriel Contreras; Mary A Dooley; Ellen M Ginzler; David Jayne; Jorge Sánchez-Guerrero; David Wofsy; Xueqing Yu; Neil Solomons
Journal:  Rheumatology (Oxford)       Date:  2009-11-20       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.